Coagulation disorders occur often in cancer patients. Thrombosis or embolism may be the first sign of an underlying malignancy. - In addition, subclinical coagulation disturbances have been found in the blood of cancer patients, for example elevated concentrations of tissue factor or thrombin- antithrombin complexes. - In 20% of the patients thrombocytosis occurs, and for lung and colon cancer it was found that thrombocytosis is an independent negative prognostic factor for survival. - The role of an activated coagulation cascade in tumour growth is not completely clear, but there is strong evidence that the formation of a temporary fibrin matrix stimulates the formation of new blood vessels (angiogenesis) and supports tumour growth and metastasis formation. - Preclinical investigations demonstrated that tumour growth and metastasis formation can be inhibited by anticoagulants. - Clinical studies suggest a beneficial effect of anticoagulants on the survival of cancer patients, but phase III randomised clinical trials should be performed to determine the effect of longterm administration of anticoagulants.
|Translated title of the contribution||Coagulation disorders in cancer patients: Possible opening for therapy|
|Number of pages||6|
|Journal||Nederlands Tijdschrift voor Geneeskunde|
|State||Published - Feb 5 2000|
ASJC Scopus subject areas